1-3 of 3
Attila Szederjesi
Close
Sort by
Journal Articles

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen

Clinical Trials & Observations
Barbara Simon, Andrea Ceglédi, János Dolgos, Péter Farkas, Manila Gaddh, László Hankó, Robert Horváth, Ambrus Kaposi, Lászlóné Magyar, Tamás Masszi, Attila Szederjesi, Nikolett Wohner, Imre Bodó
Journal: Blood
Blood (2022) 140 (18): 1983–1992.
https://doi.org/10.1182/blood.2022016873
Published: 2022
Includes: Supplemental data
Journal Articles

Description of the First Cases with ADAMTS13 Mutations in Hungary

Marienn Réti, MD, György Sinkovits, MD, Orsolya Cseprekál, MD PhD, Dorottya Csuka, PhD, Ágnes Szilágyi, PhD, Zita Farkas, MD, Zsolt Klucsik, MD, Attila Szederjesi, MSC, László Wágner, MD Prof, György Reusz, MD Prof, Johanna A. Kremer Hovinga, MD Prof, János Rigó, MD Prof, Tamas Masszi, MD Prof., Zoltan Prohászka, MD Prof
Journal: Blood
Blood (2018) 132 (Supplement 1): 5003.
https://doi.org/10.1182/blood-2018-99-118327
Published: 2018
Journal Articles

Low-Dose Combined Immunosuppression Results In Rapid Remission In Patients With Acquired Hemophilia A

Andrea Várkonyi, MD, Attila Szederjesi, János Dolgos, MD, Péter Farkas, MD, Júlia Galgóczi, Kinga Káel, Katalin Pap, Krisztina Szabó, Beata Vilimi, MD, Tamás Masszi, MD, PhD, Imre Bodó, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3589.
https://doi.org/10.1182/blood.V122.21.3589.3589
Published: 2013